New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTVVUS, ARNA, OREXVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:08 EDTOREXOrexigen and Takeda announce availability of Contrave tablets for patients
Takeda Pharmaceutical, its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A. and Orexigen Therapeutics jointly announced that Contrave extended-release tablets are now available to patients by prescription in pharmacies across the U.S.. Contrave is approved by the FDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition.
October 15, 2014
08:35 EDTOREXOrexigen earned $60M milestone payment from Takeda Pharmaceutical
Subscribe for More Information
October 10, 2014
11:38 EDTARNAArena, Eisai announce publication of BELVIQ Phase 3 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use